A Study of Evacetrapib in Healthy Participants

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether concentrations of the study drug (evacetrapib) in the blood stream is the same or is different when the person is also taking gemfibrozil (a drug used to lower lipid levels). Each participant will receive gemfibrozil alone, evacetrapib alone, and both drugs in combination. There is no washout period between doses. The safety of both of the study drugs given together will be evaluated. Information about any side effects that may have occurred will also be collected. This study will last approximately 36 days.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Evacetrapib; Gemfibrozil

Criteria

Inclusion Criteria:

• Healthy participants as determined by medical history and physical examination

• Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)

Exclusion Criteria:

• Have known allergies to evacetrapib and gemfibrozil, related compounds or any components of the formulation

• Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study

• Regularly use known drugs of abuse and/or show positive findings on urinary drug screening

• Currently smoke cigarettes or use tobacco or nicotine substitutes